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Many gene therapy strategies require transfer of high-
molecular weight DNA into human cells. To enable 
clinical trials, these vectors need to be produced on a 
large scale and at low cost. The production of effective 
high-capacity vectors like HSV-amplicons and helper-
dependent adenoviral vectors is difficult to up-scale, so 
new inexpensive vectors are needed for the efficient 
delivery of high-molecular weight DNA to human cells. 
Bacteriophage lambda vectors can accommodate up to 
about 46 kb of therapeutic DNA and can be easily 
produced in an industrial setting. However, the lambda 
vectors transfer DNA into mammalian cells with only a 
low efficiency.  It was shown that bacteriophage lambda 
virions ejected their DNA in the presence of the purified 
receptor for bacteriophage lambda, maltoporin (LamB 
protein), encoded by the malB gene of Shigella sonnei 
3070. This property of S. sonnei maltoporin was 
exploited for the bacteriophage injection-driven DNA 
loading of liposomes and other polymer nanocontainers 
displaying maltoporin. Relying on the above evidence I 
hypothesize that the efficient gene transfer by 
industrially produced bacteriophage lambda vector 
virions, such as cosmid transducing particles, to human 
cells can be accomplished after incorporation (protein 
painting) of the purified S. sonnei maltoporin into the 
human plasma membrane. 
Background  
Gene therapy strategies involving delivery of large 
therapeutic cDNAs or large cell-specific promoters require 
vectors capable of efficient transfer of high-molecular 
weight DNA to human cells (Hibbitt et al. 2007). To enable 
gene therapy clinical trials, these vectors need to be 
produced on a large scale and at low cost. However, 
effective high-capacity gene vectors such as helper-
dependent adenoviral vectors and HSV-amplicons are 
cumbersome to manufacture, especially when a large vector 
output  is  required   (Palmer  and  Ng,  2003;  Zaupa  et  al. 
2003). Therefore, there is a need for new methods of gene 
delivery that can allow efficient transfer of high molecular 
weight DNA to human cells with inexpensive gene vectors 
generated in an industrial setting.  
Gene vectors based on bacterial viruses, bacteriophages, 
can package up to about 170 kb of double stranded DNA 
and are easily produced on a large scale. However, 
bacteriophage vectors require bacterial receptors to deliver 
their genetic cargo into the cells and so can mediate genetic 
transfer to mammalian cells with only a low efficiency 
(Volcy and Dewhurst, 2009). One of the best-studied 
bacteriophages is bacteriophage lambda of 
Enterobacteriaceae which injects its DNA into recipient 
cells after attachment to its cognate bacterial receptor 
maltoporin (LamB protein). The bacteriophage lambda 
genome size is 48.5 kb, which sets the maximum capacity 
of stable lambda vectors for therapeutic DNA at about 46 
kb. It was shown that bacteriophage lambda particles 
ejected their DNA in the presence of the purified 
maltoporin receptor, encoded by the malB gene of Shigella 
sonnei 3070, while maltoporin of Escherichia coli was not 
sufficient for DNA ejection without addition of toxic 
organic solvents (Roessner et al. 1983; Roessner and Ihler, 
1987). This property of maltoporin from S. sonnei was 
exploited for bacteriophage injection-driven DNA loading 
of liposomes and other polymer nanocontainers displaying 
maltoporin (Roessner et al. 1983; Roessner and Ihler, 1987; 
Graff et al. 2002). It is a straightforward assumption that 
therapeutic liposomal gene vectors can be produced by 
injecting therapeutic DNA into liposomes using purified 
bacteriophage lambda transducing particles, that is, lambda 
virions containing non-lambda DNA (Roessner et al. 1983; 
Lambert and Rigaud, 2003). Both replication-competent 
lambda vectors and cosmids, bearing just a small fragment 
of the lambda genome with the lambda’s packaging 
sequence, can be considered for injection-driven DNA 
entrapment in the liposomal vectors.  
Injection-assisted DNA loading of maltoporin-bearing 
liposomes using bacteriophage lambda virions occurs via a 
process that does not precisely coincide with the 
mechanism existing in vivo during bacteriophage infection 
of bacteria (Esquinas-Rychen and Erni, 2001). Notably, in 
vivo bacteriophage lambda DNA injection is always 
complete, while intra-liposomal injections can be 
occasionally only partial (Roessner et al. 1983). 
Reproducible complete ejection of DNA from 
bacteriophage particles can be achieved by the addition of 
polycations to the interior compartment of the 
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proteoliposomes (Lambert and Rigaud, 2003) with 
polycations likely to be providing a pulling force for the 
entering negatively charged DNA (Inamdar et al. 2006). 
However, the employment of polycations in therapeutic 
applications can be undesirable because they are often toxic 
(Hunter 2006). In addition, in comparison to existing 
methods of DNA entrapment within liposomes (Szelei and 
Duda, 1989; Fenske and Cullis, 2005), bacteriophage 
injection-driven liposome loading appears fairly 
cumbersome. So far it was never used to prepare of 
liposomal vectors with a therapeutic genetic cargo.  
Clearly, instead of reconstitution in the liposomal 
membranes, purified maltoporin can be directly used to 
furnish the plasma membrane of target human cells 
destined for therapeutic gene transfer with bacteriophage 
lambda transducing particles. Efficient incorporation of 
exogenous integral and GPI-anchored proteins into 
mammalian cells (so-called ‘cell painting’) was previously 
described with the proteins being solubilised and delivered 
to the plasma membrane in a lipid carrier or a conventional 
mild detergent (Premkumar et al. 2001; Liu et al. 2007). 
The hypothesis  
Relying on the evidence showing injection-driven DNA 
transfer by bacteriophage lambda virions into liposomes 
bearing maltoporin receptor from S. sonnei 3070, I 
hypothesize that efficient gene transfer by the 
bacteriophage lambda vector virions, such as cosmid 
transducing particles, into human cells can be accomplished 
after painting of the cells with the purified S. sonnei 
maltoporin. Transduction of maltoporin-painted human 
cells by the DNA-ejecting lambda vector particles can be 
an efficient and up-scalable method for delivery of high 
molecular weight therapeutic DNA. 
Evaluation of the hypothesis  
In general, gene therapy can be performed in vivo and ex 
vivo. Genetic treatment in vivo involves direct 
administration of the gene vector to a patient. Ex vivo gene 
therapy consists of taking a biopsy from a patient, 
genetically modifying the cells in vitro and then 
transplanting the modified cells back to the patient. It might 
be a challenge to confirm the hypothesis in a multi-factored 
scenario of in vivo gene delivery. Therefore, the proposed 
gene transfer strategy should be initially tested in an ex vivo 
gene therapy setting with better control of the transduction 
environment in vitro. Transplantation of primary human 
fibroblasts after genetic modification ex vivo can be used as 
a treatment for a number of neurodegenerative and other 
diseases (Tuszynski et al. 2005). Primary fibroblasts are 
also simple to grow and, thus, can be used as a model cell 
population to evaluate the efficiency of the maltoporin 
painting and subsequent lambda-mediated gene delivery.  
A straightforward way to produce S. sonnei maltoporin is 
by its overexpression in a non-pathogenic host such as E. 
coli K12 harbouring a deletion of its own malB gene 
(Roessner et al. 1983). LamB is an integral membrane 
protein and its solubilization can be achieved by using 
sodium cholate, other mild detergents like Triton® X-100 
or possibly lysophosphatidylcholine, a known carrier of 
integral membrane proteins for their efficient incorporation 
into the cellular plasma membrane (Premkumar et al. 
2001). 
The cells to undergo genetic treatment are to be furnished 
with maltoporin from S. sonnei with the excess maltoporin 
thoroughly removed by washing the cells. Maltoporin is 
likely to be inserted into the plasma membrane in various 
conformations with only one conformation being a 
correctly exposed bacteriophage lambda receptor. 
Maltoporin-painted cells should be incubated with purified 
bacteriophage lambda vector particles containing 
therapeutic or marker DNA and the efficiency of gene 
transfer should be evaluated by standard methods relying 
on the transgene expression in the treated cells.  
Bacteriophages are known for their ability to pester 
industrial bacterial fermentations and so, turning misfortune 
into a blessing, the manufacture of replication competent 
bacteriophage lambda vectors on a large scale is a 
straightforward process. Non-replicating lambda 
transducing particles can be produced by cosmid packaging 
in vitro using purified proheads, tails and terminase. A 
single-strain system for the generation of lambda packaging 
extract was described by Rosenberg et al. (1985) with 
inducible phage functions being born on a cos-less helper 
prophage (Rosenberg et al. 1985). This strain can be 
adapted for a mass scale in vivo packaging of cosmid DNA 
in industrial fermenters. 
The injection of therapeutic DNA by the lambda vector 
particles into human cells can be complete, perhaps due to 
the DNA binding factors in the cytoplasm generating a 
pulling force on the DNA being ejected from the lambda 
capsids (Inamdar et al. 2006). There might be some 
differences in the repertoire of the DNA binding factors 
between various human cell types resulting in a cell-
specific variation of the efficiency of lambda injection-
mediated gene transfer.  
Lambda transducing particles inject into the recipient cells 
linear double stranded DNA with complementary 12-base 
single-stranded overhangs (cohesive ends). The linear 
status of the delivered DNA is compatible with the efficient 
gene transfer into mammalian cells (Hirata et al. 2007). If 
ligated in human cells, the cohesive ends might enable 
circularisation of the transferred DNA and its subsequent 
replication driven by the Epstein-Barr oriP-EBNA1 module 
or other replicons from circular episomes.  
Mutant versions of the maltoporin receptor, which are 
better adapted to the milieu of the mammalian plasma 
membrane, can be obtained by directed evolution strategies. 
In addition, therapeutic lambda virions can be improved by 
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a capsid display of cell-targeting ligands (Zanghi et al. 
2007) and protein moieties mediating evasion of the 
immune system.  
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